Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803675 | 0.84 | HSD17B10 (0.46) | KMT2AMEN1HSD17B10POLBSMN1; SMN2 | |
| SCHEMBL7835747 | 0.82 | HSD17B10 (0.49) | KMT2AMEN1TSHRHSD17B10TP53 | |
| SCHEMBL1129663 | 0.81 | HRH3 (0.44) | HSD17B10ALDH1A1 | |
| SCHEMBL2524274 | 0.74 | KMT2A (0.44) | KMT2AMEN1TSHRHSD17B10PIK3CA | |
| SCHEMBL30677309 | 0.73 | PIK3CA (0.43) | KMT2AMEN1TSHRHSD17B10PIK3CA | |
| SCHEMBL16423097 | 0.73 | MAPK10 (0.49) | TP53GAASMN1; SMN2MAPK1 | |
| SCHEMBL26130480 | 0.72 | PIK3CB (0.43) | KMT2AMEN1TSHRHSD17B10CDC7 | |
| SCHEMBL30677461 | 0.72 | PIK3CA (0.41) | KMT2AMEN1TSHRHSD17B10CDC7 | |
| SCHEMBL20606156 | 0.72 | KMT2A (0.41) | KMT2ATSHRHSD17B10PIK3CAPIK3CB | |
| SCHEMBL6904489 | 0.71 | TP53 (0.45) | KMT2AMEN1TSHRHSD17B10PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | claimed |
| CN-107721937-B | Preparation method and application of compound containing pyrimidone skeleton | 沈阳药科大学 | 2021-02-05 | — | — | CN | disclosed |
| US-9763900-B2 | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2017-09-19 | — | — | US | disclosed |
| US-20160106691-A1 | CHEMICAL CHAPERONINS AS NOVEL MOLECULAR MODULATORS OF BETA PROTEIN AGGREGATION PRESENT IN CONFORMATIONAL DISEASES | CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC) (CU) | 2016-04-21 | — | — | US | disclosed |
| CN-102548970-B | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SAI NUOFEI (FR) | 2015-11-25 | — | — | CN | disclosed |
| CN-102482286-B | Novel 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives, their preparation and their medical use | SANOFI SA | 2015-07-15 | — | — | CN | disclosed |
| CN-102482285-B | Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI SA | 2015-07-15 | — | — | CN | disclosed |
| EP-2097409-B1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-09-12 | — | — | EP | disclosed |
| CN-102548970-A | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| CN-102482285-A | Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS | 2012-05-30 | — | — | CN | disclosed |
| CN-102482286-A | Novel 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives, their preparation and their medical use | SANOFI SA | 2012-05-30 | — | — | CN | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| CN-101035781-A | 2-morpholino-4-pyrimidone compound | MITSUBISHI PHARMA CORP (JP) | 2007-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | DCTPP1 4204/4885KMT2A 965/4885MEN1 39/4885 |
| US-20160106691-A1 | CHEMICAL CHAPERONINS AS NOVEL MOLECULAR MODULATORS OF BETA PROTEIN AGGREGATION PRESENT IN CONFORMATIONAL DISEASES | HSPA2, HSPB1, HSP90AB2P | DCTPP1 4581/4885KMT2A 4306/4885MEN1 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.